Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia

Although the BTK inhibitor ibrutinib has transformed the management of patients with CLL, it does not induce substantial apoptosis in vitro, and as such the mechanisms underlying its ability to kill CLL cells are not well understood. Acalabrutinib, a more specific BTK inhibitor now in development, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jing, Isik, Elif, Fernandes, Stacey M., Brown, Jennifer R., Letai, Anthony, Davids, Matthew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555835/
https://www.ncbi.nlm.nih.gov/pubmed/28111464
http://dx.doi.org/10.1038/leu.2017.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555835/
https://www.ncbi.nlm.nih.gov/pubmed/28111464
http://dx.doi.org/10.1038/leu.2017.32

Ejemplares similares